Dr. Mali’s top 5 stories in ophthalmology for 2018

Dr. Mali has been appointed Medical Director for the Macular Degeneration Association

by: Joshua Mali, MD
It’s that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology for 2018:
1)  Innovations in the treatment of retinal diseases soars to new heights
As the prevalence of exudative age-related macular degeneration (wet AMD), retinal vein occlusion (RVO), and diabetic macular edema (DME) continues to climb worldwide, the ophthalmological industry has responded with amazing innovation in drug R&D, drug delivery systems, and new approved indications.
Here are the main highlights:
  • a)  Genentech continues to impress with several exciting treatments in the pipeline. Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for patients with wet AMD. In addition, further Phase II data for the Port Delivery System with ranibizumab (PDS), dosed every six months or longer, showed that visual acuity and anatomical outcomes in wet AMD are comparable to ranibizumab dosed every four weeks. Global Phase III studies in Genentech and Roche’s ophthalmology portfolio have commenced – two for faricimab in DME and one for the PDS in wet AMD. Overall, Genentech has focused on lowering the treatment burden in wet AMD, through novel mechanisms and long-acting delivery systems, and has the potential to address under-treatment and improve patient outcomes.
  • b) Regeneron’s Eylea demonstrated positive top-line results for the treatment of patients with moderately severe to severe non-proliferative diabetic retinopathy without diabetic macular edema (PANORAMA). Eylea continues to be a major force in the treatment of wet AMD, DME, and RVO……
  • Read more: http://www.ophthalmologytimes.com/lets-chat/dr-malis-top-5-stories-ophthalmology-2018
  • Source: Ophthalmology Times